Loading clinical trials...
Loading clinical trials...
Adelphi Real World Metastatic Urothelial Cancer Disease Specific Programme: Study of Real-world Data to Evaluate Patient Characteristics, Treatment Pattern and Healthcare Resource Utilisation of Locally Advanced or Metastatic Urothelial Cancer (La/mUC) at First-line Setting Post Avelumab Reimbursement in South Korea and Saudi Arabia
Conditions
Interventions
No intervention
Locations
1
South Korea
KR00001
Seoul, South Korea
Start Date
August 29, 2024
Primary Completion Date
January 31, 2025
Completion Date
January 31, 2025
Last Updated
March 24, 2025
NCT05101096
NCT02091999
NCT05390645
NCT03451331
NCT03679767
Lead Sponsor
Astellas Pharma Singapore Pte. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions